CTx-1301-Dexmethylphenidate · CTx-1301

What is CTx-1301-Dexmethylphenidate?

CTx-1301 is a dexmethylphenidate tablet formulation studied in attention-deficit/hyperactivity disorder (ADHD). Dexmethylphenidate is the active d-isomer of methylphenidate, which inhibits dopamine and norepinephrine reuptake transporters to increase neurotransmitter levels in the central nervous system.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

CTx-1301, d-MPH

Drug type

Small molecule

Targets

dopamine transporter (SLC6A3), norepinephrine transporter (SLC6A2)

Mechanism

Inhibitor of dopamine transporter (SLC6A3) and norepinephrine transporter (SLC6A2)

Pathways

dopamine reuptake inhibition, norepinephrine reuptake inhibition

Therapy area

Psychiatry

Developer

Cingulate Therapeutics (CING)

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

ADHDADHD - Combined TypeAttention Deficit Disorder With HyperactivityAttention Deficit Hyper ActivityAttention Deficit Hyperactivity DisorderAttention Deficit Hyperactivity Disorder CombinedAttention-deficit Hyperactivity

Other drugs acting on SLC6A3 / SLC6A2

Sources

• ClinicalTrials.gov NCT05286762
• ClinicalTrials.gov NCT05286762
• ClinicalTrials.gov NCT05286762
• ClinicalTrials.gov NCT05631626

Updated Oct 3, 2026. Something wrong or missing? Report it on the CING page.